[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100372519":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":45,"centralContacts":50,"locations":57,"responsibleParty":88,"collaborators":92,"id":95,"slug":55,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":55,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":60,"whyStopped":55,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"George Washington University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Ropivacaine","EXPERIMENTAL","Subjects will receive a continuous intraperitoneal infusion of ropivacaine",[13],"Drug: Ropivacaine Infusion from ON-Q Pump",{"label":15,"type":10,"description":16,"interventionNames":17},"Ropivacaine + Ketorolac","Subjects will receive a continuous intraperitoneal infusion of ropivacaine + ketorolac",[18],"Drug: Ropivacaine + Ketorolac Infusion from ON-Q Pump",{"label":20,"type":21,"description":22,"interventionNames":23},"Normal Saline","PLACEBO_COMPARATOR","Subjects will receive a continuous intraperitoneal infusion of normal saline",[24],"Drug: Normal Saline Infusion from ON-Q Pump",[26,33,39],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Ropivacaine Infusion from ON-Q Pump","Infusion of 0.2% ropivacaine at 8 mL\u002Fhour for 72 hours",[9],[32],"Naropin",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Ropivacaine + Ketorolac Infusion from ON-Q Pump","Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL\u002Fhour for 72 hours",[15],[32,38],"Toradol",{"type":27,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Normal Saline Infusion from ON-Q Pump","Infusion of 0.9% normal saline at 8 mL\u002Fhour for 72 hours",[20],[44],"Saline solution",[46],{"name":47,"affiliation":48,"role":49},"Jennifer Keller, MD","Physician","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":55,"email":56},"Radwa Aly","CONTACT","202 677 6209",null,"raly@mfa.gwu.edu",[58,77],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"MedStar Washington Hospital Center","RECRUITING","Washington D.C.","District of Columbia","20010","United States",{"type":66,"coordinates":67},"Point",[68,69],-77.03637,38.89511,{"lat":69,"lon":68},[72,76],{"name":73,"role":53,"phone":74,"phoneExt":55,"email":75},"James Robinson, MD","202-877-0526","james.k.robinson@medstar.net",{"name":73,"role":49,"phone":55,"phoneExt":55,"email":55},{"facility":78,"status":60,"city":61,"state":62,"zip":79,"country":64,"cosmosGeoPoint":80,"geoPoint":82,"contacts":83},"The GW Medical Faculty Associates","20037",{"type":66,"coordinates":81},[68,69],{"lat":69,"lon":68},[84,87],{"name":47,"role":53,"phone":85,"phoneExt":55,"email":86},"202 741 2524","jkeller@mfa.gwu.edu",{"name":47,"role":49,"phone":55,"phoneExt":55,"email":55},{"type":89,"investigatorFullName":90,"investigatorTitle":91,"investigatorAffiliation":5,"oldNameTitle":55,"oldOrganization":55},"SPONSOR_INVESTIGATOR","Ying Liu","PI",[93],{"name":94,"class":6},"Avanos Medical","100372519",false,"NCT04130464","Intraperitoneal Infusion of Analgesic for Postoperative Pain Management","The Impact of the Continuous Infusion of Intraperitoneal Analgesics on Postoperative Pain After Minimally Invasive Hysterectomy: a Randomized Controlled Trial","ON-Q","Inclusion Criteria:\n\n* Hysterectomy planned for a benign gynecologic reason (no evidence of, or concern for, malignancy in the cervix, uterus, tubes or ovaries. Benign gynecologic reasons to have a hysterectomy include fibroids, abnormal uterine bleeding, endometriosis, and pelvic pain.)\n* Patient is scheduled to have surgery with a fellowship trained minimally invasive gynecologic surgeons at one of the study sites.\n* Patient is planned for a robotic assisted total laparoscopic hysterectomy (RA-TLH) or a total laparoscopic hysterectomy (TLH).\n* Patient is capable of informed consent.\n* Patient is capable of completing the questionnaires.\n\nExclusion Criteria:\n\n* Concern for malignancy\n* The procedure is scheduled outside MIGS department.\n* Allergy to any study related medication (i.e. Ketorolac and Ropivacaine)\n* Patient is enrolled in another pain management study.",true,"FEMALE","18 Years","65 Years",{"count":107,"type":108},120,"ESTIMATED","INTERVENTIONAL",[111],"PHASE4","The study is a prospective, double-blinded, placebo-controlled multi-center trial to measure if postoperative pain and the amount of narcotics used are reduced by a clinically significant amount in women undergoing minimally invasive hysterectomy receiving a continuous infusion of intraperitoneal (IP) local anesthetic (LA) or a continuous infusion of LA combined with an NSAID compared with a control group who receives only 0.9% normal saline.",[114,115,116,117],"Hysterectomy","Gynecologic Surgical Procedures","Narcotic Use","Pain, Postoperative",[119,120,9,121],"Intraperitoneal","Pain Pump","Ketorolac Tromethamine","2026-04-03",{"date":124,"type":125},"2026-04-09","ACTUAL",{"date":127,"type":125},"2019-09-30",{"date":129,"type":108},"2026-12",{"name":90,"class":6},2]